MD3886820T2 - Formulări de capsule - Google Patents
Formulări de capsuleInfo
- Publication number
- MD3886820T2 MD3886820T2 MDE20210972T MDE20210972T MD3886820T2 MD 3886820 T2 MD3886820 T2 MD 3886820T2 MD E20210972 T MDE20210972 T MD E20210972T MD E20210972 T MDE20210972 T MD E20210972T MD 3886820 T2 MD3886820 T2 MD 3886820T2
- Authority
- MD
- Moldova
- Prior art keywords
- compound
- solid solution
- relates
- capsule formulations
- methods
- Prior art date
Links
- 239000007963 capsule composition Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 abstract 3
- 239000006104 solid solution Substances 0.000 abstract 3
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 2
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 abstract 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Prezenta invenţie se referă la formulări de capsule cu soluţie solidă de compus 1 şi metode de obţinere a acestora. De asemenea, prezenta invenţie se referă la metode de tratare a indivizilor, care suferă sau sunt susceptibili la o boală sau o tulburare, care implică activarea patologică a receptorilor c5a, prin administrarea unei cantităţi eficiente de una sau mai multe capsule cu soluţie solidă care conţine compusul 1. De asemenea, invenţia se referă la capsule cu doza unică, care conţin anumite cantităţi de compus 1, şi truse care cuprind o capsulă cu soluţie solidă cu conţinut de compus 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/063547 WO2020112961A1 (en) | 2018-11-30 | 2019-11-27 | Capsule formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3886820T2 true MD3886820T2 (ro) | 2023-07-31 |
Family
ID=70849818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20210972T MD3886820T2 (ro) | 2018-11-30 | 2019-11-27 | Formulări de capsule |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20200170957A1 (ro) |
| EP (2) | EP3886820B8 (ro) |
| JP (1) | JP7342124B2 (ro) |
| KR (1) | KR102586747B1 (ro) |
| CN (1) | CN113164403A (ro) |
| AR (1) | AR117219A1 (ro) |
| AU (1) | AU2019389031B2 (ro) |
| BR (1) | BR112021010285A2 (ro) |
| CA (1) | CA3120999A1 (ro) |
| CL (1) | CL2021001389A1 (ro) |
| CY (1) | CY1126079T1 (ro) |
| DK (1) | DK3886820T3 (ro) |
| ES (1) | ES2943492T3 (ro) |
| FI (1) | FI3886820T3 (ro) |
| HR (1) | HRP20230551T1 (ro) |
| HU (1) | HUE062551T2 (ro) |
| IL (1) | IL283450B2 (ro) |
| LT (1) | LT3886820T (ro) |
| MA (1) | MA54318B1 (ro) |
| MD (1) | MD3886820T2 (ro) |
| MX (1) | MX2021006242A (ro) |
| PL (1) | PL3886820T3 (ro) |
| PT (1) | PT3886820T (ro) |
| RS (1) | RS64250B1 (ro) |
| SG (1) | SG11202105572UA (ro) |
| SI (1) | SI3886820T1 (ro) |
| TW (1) | TWI827745B (ro) |
| WO (1) | WO2020112961A1 (ro) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
| US11844790B2 (en) * | 2020-10-28 | 2023-12-19 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| WO2023225533A1 (en) * | 2022-05-19 | 2023-11-23 | Dow Global Technologies Llc | Use of peg-based interpolymer complexes for improved solubilization of bcs class ii drugs |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| EP1817012A2 (en) * | 2004-11-24 | 2007-08-15 | Merck & Co., Inc. | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| CA2965223C (en) | 2008-12-22 | 2019-09-24 | Chemocentryx, Inc. | C5ar antagonists |
| JP5717768B2 (ja) * | 2010-03-10 | 2015-05-13 | アッヴィ・バハマズ・リミテッド | 固体組成物 |
| JP2013529647A (ja) * | 2010-06-24 | 2013-07-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| CA2940984A1 (en) | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
| EP3682879B1 (en) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| WO2017123716A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
| RU2748260C2 (ru) | 2016-04-04 | 2021-05-21 | Кемосентрикс, Инк. | РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ |
| EP4272821A3 (en) | 2017-04-03 | 2024-01-03 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
| US10376595B2 (en) * | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| EP3703687A4 (en) | 2017-10-30 | 2021-04-07 | ChemoCentryx, Inc. | DEUTERATED COMPOUNDS USED AS IMMUNOMODULATORS |
| JP2021501159A (ja) | 2017-10-31 | 2021-01-14 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 |
| MA52808A (fr) | 2018-06-07 | 2021-04-14 | Chemocentryx Inc | Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca |
| WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
-
2019
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/en active Application Filing
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/en active Active
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/en active Active
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 CA CA3120999A patent/CA3120999A1/en active Pending
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active IP Right Grant
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
-
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3886820T2 (ro) | Formulări de capsule | |
| MA35920B1 (fr) | Composés destinés au traitement de l'amyotrophie spinale | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| CL2022000195A1 (es) | Usos para tratar la enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384) | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| CR10347A (es) | Anticuerpos contra el peptidob-amiloide | |
| MX2017010544A (es) | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. | |
| EA201290836A1 (ru) | Связанные бис-арильные арилтриазолоны и их применение | |
| MA39193B1 (fr) | Modulateurs du gpr6 à base de tétrahydropyridopyrazines | |
| MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| EA202090573A1 (ru) | Составы нирапариба | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| FR3034993B1 (fr) | Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| MD3762368T2 (ro) | Compuși diol aminopirazină ca inhibitori ai PI3K-Y | |
| EA202190662A1 (ru) | Фармацевтические комбинации для лечения опухоли, содержащие антитело к cd19 и естественные клетки-киллеры | |
| BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| EA202092695A1 (ru) | Композиции, содержащие глюкозу и гемицеллюлозу, и их применение | |
| MX2019007942A (es) | Uso de dapansutrilo para el tratamiento de enfermedades cardiovasculares. | |
| MX2021001780A (es) | Composiciones para el tratamiento de telas que comprenden capsulas de agente de beneficio. | |
| MX2020010266A (es) | Radiofarmaco dirigido a antigeno de membrana especifico de prostata (psma) para diagnosticar y tratar el cancer de prostata. | |
| EA201891610A1 (ru) | Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| EA201992389A1 (ru) | Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение | |
| CL2018001719A1 (es) | Tratamiento contra el mieloma múltiple (divisional solicitud 201600396) |